Prognostic Significance of Systemic Immune Inflammatory Index in NSCLC: a Meta-analysis

Overview

Journal Lung Cancer Manag

Date 2024 May 30

PMID 38812771

Authors

Wen-Hua Chen

Jing-Jing Shao

Ying Yang

Yun Meng

Sheng Huang

Rong-Fang Xu

Ji-Bin Liu

Jian-Guo Chen

Qin Wang

Hai-Zhen Chen

Affiliations

Soon will be listed here.

Abstract

The aim of this meta-analysis was to investigate the relationship between the baseline systemic immune inflammatory index (SII) and prognosis in patients with NSCLC. The relation between pretreatment SII and overall survival, disease-free survival, cancer-specific survival, progression-free survival and recurrence-free survival in NSCLC patients was analyzed combined with hazard ratio and 95% CI. The results showed that high SII was significantly correlated with overall survival and progression-free survival of NSCLC patients, but not with disease-free survival, cancer-specific survival and recurrence-free survival. The study suggests that a higher SII has association with worse prognosis in NSCLC patients. CRD42022336270.

Citing Articles

The prognostic role of systemic immune-inflammation index, SII, in Metastatic Castration-Resistant Prostate Cancer patients.

Uzun M, Gokcek S, Kaya E, Semiz H Discov Oncol. 2025; 16(1):317.

PMID: 40085163 DOI: 10.1007/s12672-025-02084-3.

Molecular subtypes and prognostic factors of lung large cell neuroendocrine carcinoma.

Liu T, Chen X, Mo S, Zhou T, Ma W, Chen G Transl Lung Cancer Res. 2024; 13(9):2222-2235.

PMID: 39430332 PMC: 11484736. DOI: 10.21037/tlcr-24-292.

References

Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K . Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer. 2009; 45(11):1950-8. DOI: 10.1016/j.ejca.2009.01.023. View

Li H, Wang G, Zhang H, Song X, Cao J, Zhang X . Prognostic role of the systemic immune-inflammation index in brain metastases from lung adenocarcinoma with different EGFR mutations. Genes Immun. 2018; 20(6):455-461. DOI: 10.1038/s41435-018-0050-z. View

Zhang N, Jiang J, Tang S, Sun G . Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis. Int Immunopharmacol. 2020; 85:106677. DOI: 10.1016/j.intimp.2020.106677. View

Tong Y, Tan J, Zhou X, Song Y, Song Y . Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. J Transl Med. 2017; 15(1):221. PMC: 5664920. DOI: 10.1186/s12967-017-1326-1. View

Takeda T, Yamada T, Tanimura K, Nakano T, Ishida M, Tachibana Y . Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib. Diagnostics (Basel). 2021; 11(12). PMC: 8699991. DOI: 10.3390/diagnostics11122170. View

Li B, Wang S, Li C, Guo M, Xu Y, Sun X . The Kinetic Changes of Systemic Inflammatory Factors during Bevacizumab Treatment and Its Prognostic Role in Advanced Non-small Cell Lung Cancer Patients. J Cancer. 2019; 10(21):5082-5089. PMC: 6775608. DOI: 10.7150/jca.30478. View

Fu F, Deng C, Wen Z, Gao Z, Zhao Y, Han H . Systemic immune-inflammation index is a stage-dependent prognostic factor in patients with operable non-small cell lung cancer. Transl Lung Cancer Res. 2021; 10(7):3144-3154. PMC: 8350100. DOI: 10.21037/tlcr-21-267. View

Deng C, Zhang N, Wang Y, Jiang S, Lu M, Huang Y . High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs. Medicine (Baltimore). 2019; 98(33):e16875. PMC: 6831201. DOI: 10.1097/MD.0000000000016875. View

Greten F, Grivennikov S . Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019; 51(1):27-41. PMC: 6831096. DOI: 10.1016/j.immuni.2019.06.025. View

10.

Liu J, Li S, Zhang S, Liu Y, Ma L, Zhu J . Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. J Clin Lab Anal. 2019; 33(8):e22964. PMC: 6805305. DOI: 10.1002/jcla.22964. View

11.

Herrmann D, Sinnett P, Holmes J, Khan S, Koller C, Vassar M . Statistical controversies in clinical research: publication bias evaluations are not routinely conducted in clinical oncology systematic reviews. Ann Oncol. 2017; 28(5):931-937. DOI: 10.1093/annonc/mdw691. View

12.

Punjabi A, Barrett E, Cheng A, Mulla A, Walls G, Johnston D . Neutrophil-Lymphocyte Ratio and Absolute Lymphocyte Count as Prognostic Markers in Patients Treated with Curative-intent Radiotherapy for Non-small Cell Lung Cancer. Clin Oncol (R Coll Radiol). 2021; 33(8):e331-e338. DOI: 10.1016/j.clon.2021.03.019. View

13.

Li X, Hu P, Liu J, Zhang J, Liu Q . Systemic immune-inflammation index predicted overall survival and radiosensitivity in advanced non-small-cell lung cancer. Future Oncol. 2020; 16(5):103-115. DOI: 10.2217/fon-2019-0761. View

14.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

15.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

16.

Bilgetekin I, Bugdayci Basal F . Systemic Immune-inflammation Index is the Best Prognostic Factor in Patients with Advanced Stage Adenocarcinoma of the Lung Treated with Pemetrexed. J Coll Physicians Surg Pak. 2020; 30(9):933-939. DOI: 10.29271/jcpsp.2020.09.933. View

17.

Zhang Y, Chen B, Wang L, Wang R, Yang X . Systemic immune-inflammation index is a promising noninvasive marker to predict survival of lung cancer: A meta-analysis. Medicine (Baltimore). 2019; 98(3):e13788. PMC: 6370019. DOI: 10.1097/MD.0000000000013788. View

18.

Jin Y, Sun Y, Shi X, Zhao J, Shi L, Yu X . Prognostic value of circulating C-reactive protein levels in patients with non-small cell lung cancer: a systematic review with meta-analysis. J Cancer Res Ther. 2014; 10 Suppl:C160-6. DOI: 10.4103/0973-1482.145854. View

19.

Zhang H, Gao L, Zhang B, Zhang L, Wang C . Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: a systematic review and meta-analysis. Sci Rep. 2016; 6:22618. PMC: 4778054. DOI: 10.1038/srep22618. View

20.

E Y, He N, Wang Y, Fan H . Percutaneous transluminal angioplasty (PTA) alone versus PTA with balloon-expandable stent placement for short-segment femoropopliteal artery disease: a metaanalysis of randomized trials. J Vasc Interv Radiol. 2008; 19(4):499-503. DOI: 10.1016/j.jvir.2007.12.446. View